Nomos takes ultrasound-guided radiation therapy to China
This article was originally published in Clinica
Executive Summary
North American Scientific's radiation oncology division, Nomos, has received approval in China to market its ultrasound system for viewing cancerous tumors prior to the delivery of radiation therapy. The image-guided radiation therapy (IGRT) system, called BAT Sxi, is designed to be compatible with all linear accelerators and most treatment planning products, said the Chatsworth, California firm. Noting that it had gained Chinese market go-ahead for its Peacock intensity-modulated radiation therapy (IMRT) product in September 2005, the company said it remained hopeful that it would have its full range of products available in China during fiscal 2006. The firm is also in the process of registering in China its Prospera I-125 brachytherapy seeds for treating prostate cancer.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.